Enveric Biosciences, Inc.
ENVB· Nasdaq
Filed Mar 31, 2022 · 10-K · 90 days after period end · 0001493152-22-008510
derived · Computed from the longer spans the company filed.
| Metric | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019dderived from reported figures | Q4 2018dderived from reported figures |
|---|---|---|---|---|
| Revenue | — | — | $9.06M | $10.28M |
| Net Income | -$42.11M | -$2.55M | -$2.53M | -$19.77M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Enveric Biosciences, Inc. · CIK 890821 · Engraved from SEC EDGAR
ended Dec 31, 2021 · filed Mar 31, 2022 · 90 d after period end